Edwards Lifesciences Corporation (EW)

Market Cap	45.74B +14.5%
Revenue (ttm)	6.07B +11.5%
Net Income	1.07B -74.3%
EPS	1.83 -73.7%
Shares Out	576.54M
PE Ratio	43.83
Forward PE	26.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,948,380
Open	81.80
Previous Close	82.10
Day's Range	78.57 - 81.84
52-Week Range	65.94 - 87.89
Beta	0.93
Analysts	Buy
Price Target	96.47 (+21.59%)
Earnings Date	Apr 22, 2026

About EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 16,000
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Analyst Summary

According to 21 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $96.47, which is an increase of 21.59% from the latest price.

Price Target

$96.47

(21.59% upside)

Analyst Consensus: Buy